Target selection for deep brain stimulation in treatment resistant schizophrenia

Iluminada Corripio,Alexandra Roldán,Peter McKenna,Salvador Sarró,Anna Alonso-Solís,Laura Salgado,Enric Álvarez,Joan Molet,Edith Pomarol-Clotet,Maria Portella

DOI: https://doi.org/10.1016/j.pnpbp.2021.110436

2022-01-01

Abstract:The use of deep brain stimulation (DBS) in treatment resistant patients with schizophrenia is of considerable current interest, but where to site the electrodes is challenging. This article reviews rationales for electrode placement in schizophrenia based on evidence for localized brain abnormality in the disorder and the targets that have been proposed and employed to date. The nucleus accumbens and the subgenual anterior cingulate cortex are of interest on the grounds that they are sites of potential pathologically increased brain activity in schizophrenia and so susceptible to the local inhibitory effects of DBS; both sites have been employed in trials of DBS in schizophrenia. Based on other lines of reasoning, the ventral tegmental area, the substantia nigra pars reticulata and the habenula have also been proposed and employed. The dorsolateral prefrontal cortex has not been suggested, probably reflecting the evidence that it is underactive rather than overactive in schizophrenia. The hippocampus is also of theoretical interest but there is no clear functional imaging evidence that it shows overactivity in schizophrenia. On current evidence, the nucleus accumbens may represent the strongest candidate for DBS electrode placement in schizophrenia, with the substantia nigra pars reticulata also showing promise in a single case report; the ventral tegmental area is also of potential interest, though it remains untried.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology